This success story is about AIDSTAR-One's collaboration with seven universities and three regional health sciences colleges in Ethiopia to improve pre-service education in infection prevention and control and patient safety.
This success story is about the success of AIDSTAR-One in developing positive attitudes through training for improving practices of health care workers and supportive supervision.
This success story is about the success of AIDSTAR-One in establishing a system working with a private company and health centers for recycling plastic healthcare wastes.
The story is about the success of AIDSTAR-One advocacy for protecting health care workers with Hepatitis-B vaccination.
The story is about the success of AIDSTAR-One in leveraging resources from government as well as USG partners for health care waste management.
AIDSTAR-One successfully linked health facilities with the company immediately following health facility training so that managers knew where they could procure safety boxes locally. A Laboratory Scientist, Badung Bitrus PAM (Jos University Teaching Hospital) noted, “the safety boxes are of high quality, it is a good thing that we now have a local manufacturing company in Nigeria.”
In order to facilitate the country-wide implementation of the safe phlebotomy strategy, AIDSTAR-One supported the Government of Nigeria in developing training materials based on the WHO Guidelines on Drawing Blood: Best Practices in Phlebotomy (2010) and incorporated the new guidelines into existing training manuals on injection safety and safe health care waste management. AIDSTAR-One also trained Nigerian health care instructors to update their knowledge and skills before they began in-service training for health workers. Currently, all health workers in the targeted sites are being trained on safe phlebotomy along with injection safety and health care waste management.
Hundreds of tons of pharmaceuticals are shipped into or produced within low- and middle-income countries each year to treat the approximately 4 million HIV-positive individuals currently receiving antiretroviral therapy (ART) and taking antiretroviral (ARV) drugs. The vast majority of these medicines are taken by the people who need them, but a fraction—whether through changes in treatment regimens or through issues with procurement or supply chain management—expire before they can be used. Even this fraction, however, equates to tons of dangerous medical waste.